Pembrolizumab and Cabozantinib in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma (RMHNSCC): 2-year Long Term Survival Update with Biomarker Analysis

Anti-programmed cell death protein 1 (PD-1) therapy is a standard of care in recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC). Vascular endothelial growth factor receptor tyrosine kinase inhibitors have immunomodulatory properties and may improve clinical outcomes in combination with anti-PD-1 therapy. Pembrolizumab and cabozantinib were well tolerated and showed promising clinical activity in patients with RMHNSCC in our reported phase 2 trial. Baseline CD8+ T cell infiltration correlated with overall response rate (ORR) (p=0.0512).

Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: N.F. Saba, A. Ekpenyong, A. McCook, N.C. Schmitt, J.H. Gross, S.F. Rudra, W.A. Stokes, K. Kirtane, R. Chaudhary, M. Biernacki, R. Slebos, X. Song, C. Steuer, D.M. Shin, Y.F. Teng, Y. Liu, C.H. Chung Tags: 2 Source Type: research